Related Research Articles
Molecular biology is a branch of biology that concerns the molecular basis of biological activity in and between cells, including molecular synthesis, modification, mechanisms and interactions.
Johnson & Johnson is an American multinational corporation founded in 1886 that develops medical devices, pharmaceutical and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 37 on the 2018 Fortune 500 list of the largest United States corporations by total revenue. J&J is one of the world's most valuable companies.
Abbott Laboratories is an American medical devices and health care company with headquarters in the Abbott Park Business Center in Lake Bluff, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off the research-based pharmaceuticals into AbbVie in 2013.
Adalimumab, sold under the brand name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. Use is generally only recommended in people who have not responded to other treatments. It is used by injection under the skin.
Sir Gregory Paul Winter is a Nobel Prize-winning British biochemist best known for his work on the therapeutic use of monoclonal antibodies. His research career has been based almost entirely at the MRC Laboratory of Molecular Biology and the MRC Centre for Protein Engineering, in Cambridge, England.
Biocon Limited is an Indian biopharmaceutical company based in Bangalore, India. The Company manufactures generic active pharmaceutical ingredients (APIs) that are sold in over 120 countries [no proof provided] across the globe, including the developed markets of the United States and Europe. It also manufactures novel biologics, as well as, biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets [provide reference]. In research services, Syngene International Limited (Syngene), a publicly listed subsidiary of Biocon.
Venrock, a compound of "Venture" and "Rockefeller", is a venture capital firm formed in 1969 to build upon the successful investing activities of the Rockefeller family that began in the late 1930s. It has offices in Palo Alto, California, New York City, and Boston, Massachusetts.
Alan G. Walton OBE was a scientist, businessman, and venture capitalist. He was born in England in 1936 and earned a Ph.D. from the University of Nottingham. He worked for twenty years as a professor at Case Western Reserve University and later served as the Chairman of Oxford Bioscience Corporation. Walton was instrumental in the development and funding of the Human Genome Project. Through his association with Oxford Bioscience, Walton managed over $850 million in a portfolio that included 80 companies. In 2012, he was awarded the Order of the British Empire by Queen Elizabeth II. He died in 2015 at his home in Westport, Connecticut.
An anti-CD22 immunotoxin is a monoclonal antibody linked to a cytotoxic agent. They are being studied in the treatment of some types of B-cell cancer.
Cambridge Antibody Technology was a biotechnology company headquartered in Cambridge, England, United Kingdom. Its core focus was on antibody therapeutics, primarily using Phage Display and Ribosome Display technology.
Briakinumab (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.
John McCafferty is a British scientist, one of the founders of Cambridge Antibody Technology alongside Sir Gregory Winter and David Chiswell. He is well known as one of the inventors of scFv antibody fragment phage display, a technology that revolutionised the monoclonal antibody drug discovery. McCafferty and his team developed this process following failures previously generating antibodies by immunizing mice. Later improvements of antibody phage display technology enables the display of millions of different antibody fragments on the surface of filamentous phage and subsequent selection of highly specific recombinant antibodies to any given target. This technology is widely exploited in pharmaceutical industry for the discovery and development of therapeutic monoclonal antibodies to treat mainly cancer, inflammatory and infectious diseases. One of the most successful was HUMIRA (adalimumab), discovered by Cambridge Antibody Technology as D2E7 and developed and marketed by Abbott Laboratories. HUMIRA, an antibody to TNF alpha, was the world's first phage display derived fully human antibody, which achieved annual sales exceeding $1bn therefore achieving blockbuster status. Humira went on to dominate the best-selling drugs lists - in 2016: The best selling drugs list researched by Genetic Engineering & Biotechnology News, published in March 2017, details that Humira occupied the number 1 position for 2015 and 2016. Whilst for 2017, Abbvie reports that Humira achieved $18.427billion of sales in 2017
Cai Mingjie is a Singaporean taxicab driver and former biology researcher, known for his blog, A Singapore Taxi Driver's Diary. He is described variously as "Singapore's most educated taxi driver" and "the only taxi driver with a Ph.D.".
Francesco De Rubertis is a partner at medicxi, a venture capital firm with offices in London, Jersey and Geneva, having co-founded the firm in February 2016. Prior to that he was a partner at another venture capital firm, Index Ventures, having led the firm's efforts to establish its life sciences practice after joining in 1997.
Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug Conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
David Grainger is a partner at medicxi, a European life sciences-oriented venture capital firm and chief executive officer of Methuselah Health Ltd., a drug development company doing proteomics research in the longevity space.
Asset-centricity is an approach to investing in the life sciences field with a focus on key assets, such as a pharmaceutical molecule that could form the basis for a novel new drug which has already been identified, rather than on discovering such assets through basic research & development.
References
- 1 2 "Backed by J&J and Glaxo, veteran VC group splits from Index, unveils $227M fund". FierceBiotech. February 1, 2016.
- 1 2 "J&J and GSK join Medicxi's European life sciences push". FT. February 2, 2016.
- ↑ "Index Ventures appoints antibody expert as partner". MedNous. September 3, 2010.
- ↑ "News". Index Ventures. Archived from the original on 2014-02-14. Retrieved 2012-07-31.
- ↑ "Abbott Shells Out $170M for PanGenetics' Early-Stage Chronic Pain Therapeutic". Genetic Engineering News. November 12, 2009.
- ↑ "Diartis Pharmaceuticals - Press Releases". Diartispharma.com. 2011-02-16. Archived from the original on 2012-04-20. Retrieved 2012-07-31.
- ↑ "Index appoints Johnson partner". Scripintelligence. 2010-09-02. Retrieved 2012-07-31.
- ↑ "Home : Genesis 2019". Archived from the original on November 29, 2010. Retrieved February 22, 2011.
- ↑ "Home" (PDF). Scripintelligence. Archived from the original (PDF) on 2012-03-14. Retrieved 2012-07-31.